Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2032-2041

  Blumer, Jeffrey ^a   Rodriguez, Adib ^b   Sánchez, Pablo J ^c   Sallas, William ^d   Kaiser, Guenther ^d   Hamed, Kamal ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Hospital Infantil de Infectologia Y Rehabilitacion   (Guatemala)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXYPENCICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; PHARMACOLOGICAL PARAMETERS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SINGLE DRUG DOSE; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

2-AMINOPURINE; ACYCLOVIR; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BODY WEIGHT; CAPSULES; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES SIMPLEX; HUMANS; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL;

EID: 77951241946     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01508-09     Document Type: Article

References (32)

1. Abudalu, M., S. Tyring, W. Koltun, N. Bodsworth, and K. Hamed. 2008. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin. Infect. Dis. 47:651-658.
2. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
3. Aoki, F. Y., S. Tyring, F. Diaz-Mitoma, G. Gross, J. Gao, and K. Hamed. 2006. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 42:8-13.
4. Bacon, T. H., M. J. Levin, J. J. Leary, R. T. Sarisky, and D. Sutton. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16:114-128.
5. Bodsworth, N., M. Bloch, A. McNulty, I. Denham, N. Doong, S. Trottier, M. Adena, M. A. Bonney, J. Agnew, et al. 2008. Two-day versus five-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex. Health 5:219-225.
6. Bodsworth, N., K. Fife, W. Koltun, S. Tyring, M. Abudalu, M. Prichard, and K. Hamed. 2009. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr. Med. Res. Opin. 25:483-487.
7. Breuer, J., and R. Whitley. 2007. Varicella-zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl. 2):25-29.
8. Crumpacker, C. 1996. The pharmacological profile of famciclovir. Semin. Dermatol. 15(Suppl. 1):14-26.
9. Eksborg, S. 2003. The pharmacokinetics of antiviral therapy in paediatric patients. Herpes 10:66-71.
10. Gill, K. S., and M. J. Wood. 1996. The clinical pharmacokinetics of famciclovir. Clin. Pharmacokinet. 31:1-8.
11. Kearns, G. L., S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman. 2003. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N. Engl. l J. Med. 349:1157-1167.
12. Kimberlin, D. W. 2007. Herpes simplex virus infections of the newborn. Semin. Perinatol. 31:19-25.
13. MacDougall, C., and B. J. Guglielmo. 2004. Pharmacokinetics of valaciclovir. J. Antimicrob. Chemother. 53:899-901.
14. Ogungbenro, K., I. Matthews, M. Looby, G. Kaiser, G. Graham, and L. Aarons. 2009. Population pharmacokinetics and optimal design of paediatric studies for famciclovir. Br. J. Clin. Pharmacol. 68:546-560.
15. Pue, M. A., and L. Z. Benet. 1993. Pharmacokinetics of famciclovir in man. Antivir. Chem. Chemother. 4(Suppl. 1):47-55.
16. Pue, M. A., S. K. Pratt, A. J. Fairless, S. Fowles, J. Laroche, P. Georgiou, and W. Prince. 1994. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33:119-127.
17. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed. Lippincott/The Williams & Wilkins Co., Philadelphia, PA.
18. Sacks, S. L., F. Y. Aoki, A. Y. Martel, S. D. Shafran, and M. Lassonde. 2005. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin. Infect. Dis. 41:1097-1104.
19. Sáez-Llorens, X., R. Yogev, A. Arguedas, A. Rodriguez, M. G. Spigarelli, T. De Leon Castrejon, L. Bomgaars, M. Roberts, B. Abrams, W. Zhou, M. Looby, G. Kaiser, and K. Hamed. 2009. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob. Agents Chemother. 53:1912-1920.
20. Sauerbrei, A., and P. Wutzler. 2007. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. 2. Varicella-zoster virus infections. Med. Microbiol. Immunol. 196:95-102.
21. Shen, M. C., H. H. Lin, S. S. Lee, Y. S. Chen, P. C. Chiang, and Y. C. Liu. 2004. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J. Microbiol. Immunol. Infect. 37:75-81.
22. Simpson, D., and K. A. Lyseng-Williamson. 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 66:2397-2416.
23. Skoldenberg, B. 1996. Herpes simplex encephalitis. Scand. J. Infect. Dis. Suppl. 100:8-13.
24. Spruance, S. L., N. Bodsworth, H. Resnick, M. Conant, C. Oeuvray, J. Gao, and K. Hamed. 2006. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J. Am. Acad. Dermatol. 55:47-53.
25. Strolin Benedetti, M., and E. L. Baltes. 2003. Drug metabolism and disposition in children. Fundam. Clin. Pharmacol. 17:281-299.
26. Tayama, Y., K. Miyake, K. Sugihara, S. Kitamura, M. Kobayashi, S. Morita, S. Ohta, and K. Kihira. 2007. Developmental changes of aldehyde oxidase activity in young Japanese children. Clin. Pharmacol. Ther. 81:567-572.
27. Tetelbaum, M., Y. Finkelstein, A. A. Nava-Ocampo, and G. Koren. 2005. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr. Rev. 26:321-328.
28. Tod, M., F. Lokiec, R. Bidault, F. De Bony, O. Petitjean, and Y. Aujard. 2001. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob. Agents Chemother. 45:150-157.
29. Tyring, S. K., F. Diaz-Mitoma, S. D. Shafran, L. A. Locke, S. L. Sacks, and C. L. Young. 2003. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J. Cutan. Med. Surg. 7:449-454.
30. Vinh, D. C., and F. Y. Aoki. 2006. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 7:2271-2286.
31. Wharton, M. 1996. The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. N. Am. 10:571-581.
32. Whitley, R. J. 2008. Therapy of herpesvirus infections in children. Adv. Exp. Med. Biol. 609:216-232.